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Abstract
Objectives Evidence-based guidelines have the potential to reduce variation
and increase prescribing quality. Identifying the key determinants to their
uptake, using a theory-based approach, may assist in the design of successful
interventions to increase their adoption into practice. This systematic review
investigated barriers and facilitators identified using the Theoretical Domains
Framework (TDF) to the implementation of prescribing guidelines.
Methods Electronic databases (EMBASE, PubMed) were searched. Studies were
included if they used the TDF to identify key determinants of guideline imple-
mentation. Only studies published in English were included.
Key findings Of the 407 studies identified, 15 were included. A range of patient
populations and therapeutic categories were represented. Multiple determinants
were identified that affected guideline implementation, with similarities and dif-
ferences identified across studies. Barriers to guideline adoption included time
restriction, lack of awareness, guideline complexity, lack of clinical evidence,
social influences and disagreement. Facilitators included peer influence, guideline
simplicity, confidence and belief about the positive consequences derived from
guideline adoption, for examples improved care and patient outcomes.
Conclusions Multiple behavioural factors affect the adoption of prescribing
guidelines. The results aided the understanding of factors that may be targeted
to increase guideline compliance. However, barriers and facilitators can vary
significantly in different environments; therefore, research that targets particular
healthcare settings and patient populations may provide further evidence to
increase the specificity and credibility of intervention strategies.
Background
Guidelines are ‘systematically developed statements to
assist practitioner and patient decisions about appropriate
health care for specific clinical circumstances’.[1] Their
purpose is to promote effective and cost-effective decision-
making for patient care.[2] Guidelines are instrumental in
translating complex scientific research into simplified rec-
ommendations that can increase healthcare quality and
outcomes and reduce inappropriate variation in prac-
tice.[1,3] It has been estimated, however, that 30–40% of
patients receive non-evidence-based treatment and 20–
25% are prescribed medication that is not beneficial and
may even potentially cause harm.[4] These findings suggest
that guidelines are not always implemented as intended.
There has been extensive exploration of the challenges
associated with guideline implementation leading to the
development of intervention strategies to improve their
adoption.[5,6] Several systematic reviews have identified
that the majority of guideline implementation research
does not address the key determinants of guideline
uptake.[7–11] These determinants include ‘barriers’ and ‘fa-
cilitators’ that hinder or encourage implementation,
respectively.[12] One review of 26 randomised controlled
trials concluded that interventions that were tailored to
address barriers were more likely to improve practice.[13]
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A theoretical approach may be helpful in identifying
behavioural factors that can be targeted by guideline imple-
mentation interventions.[7,14] The Theoretical Domains
Framework (TDF) is one such theoretical approach.[15] It
has been widely used to explore determinants of different
behaviours including prescribing, but to date, these studies
have not been synthesised to derive any additional learning
from the application of this framework.[16]
The aim of this systematic review was to identify studies
which had applied the TDF to identify barriers and facilita-
tors to the adoption of prescribing guidelines, and to
explore commonly occurring domains relevant to this beha-
viour. This review also explored whether domains varied by
the prescribing behaviour targeted, that is prescribing for
specific patient populations or therapeutic groups.
Method
Standard systematic review methods were applied. No
ethical approval was required. A PRISMA checklist was
completed for this review[17] (Appendix S1). Electronic
databases (EMBASE, PubMed) were searched for the per-
iod 2005 to 13 November 2018. A total of four searches
were conducted using different word combinations to find
relevant studies. The first search combined the words
‘TDF’, ‘Theoretical Domains Framework’ or ‘Theoretical
Domain Framework’. The second search included ‘Bar-
rier’, ‘Barriers’, ‘Facilitators’, ‘Facilitate’, ‘Facilitates’,
‘Help’, ‘Helps’, ‘Hinder’, ‘Hinders’, ‘Behaviour Change’ or
‘Behavior Change’. The third search was undertaken using
the words ‘Guideline’, ‘Guidelines’, ‘Prescribing’, ‘Pre-
scribe’, ‘Protocol’, ‘Protocol Compliance’ or ‘Prescrip-
tion’. The fourth search combined all preceding searches
to conclude studies eligible for screening (Appendix S2).
Duplicate independent screening of the titles and abstracts
was undertaken by two pairs of assessors. The full texts of
potentially eligible studies were retrieved and underwent
duplicate independent assessment for suitability of inclusion.
The reference list of each included study was checked for
additional relevant studies. The search was repeated on 5
December 2018 to identify any additional studies and con-
struct a PRISMA flow diagram (Figure 1).
Inclusion criteria
Primary research studies using data collection methods
such as interviews, surveys or focus groups to explore
prescribers’ views were eligible for inclusion. Studies were
included if the TDF was used to investigate the adoption
of prescribing guidelines in a healthcare setting. Partici-
pants were medical or non-medical prescribers. The TDF
was introduced in 2005; hence, the date range used for
the search. No restrictions were imposed on country of
origin; however, only studies written in the English lan-
guage were included due to time and financial constraints.
Only full publications were included.
Exclusion criteria
Studies that used the TDF to explore barriers and facilita-
tors of prescribing but did not include guidelines were
excluded. Studies exploring barriers and facilitators of
guideline uptake but not involving prescribing of medica-
tion were excluded.
Data Extraction and Analysis
Duplicate independent data extraction was undertaken
using a data extraction form (Appendix S3). Data were
grouped by characteristics of prescribers, the target
patients, setting and study design (Tables 1,2).
Results
A total of 407 studies were identified by the electronic
searches. Thirty full texts were retrieved, and 15 fulfilled
inclusion criteria. The majority of studies used a mixed-
methods approach (n = 6) or interviews (n = 6) to obtain
data. Focus groups (n = 2) and surveys (n = 1) were
alternative methods used for data collection. The studies
were conducted in Australia (n = 6), Canada (n = 4), the
United Kingdom (n = 2), New Zealand (n = 1), the
Netherlands (n = 1), Ireland (n = 1) and Lao People’s
Democratic Republic (n = 1). Five studies explored pre-
scribing for the general population including three studies
that examined prescribing in emergency care[18–20] and
two studies of patients with co-morbidities in primary
care.[21,22. Four studies investigated prescribing for chil-
dren,[23–26] and three explored prescribing in pregnancy
and preconception.[27–29] The three remaining studies
investigated prescribing for the elderly.[30–32] Three of the
included studies explored antibiotic prescribing.[20,23,30]
Multiple determinants were identified that affected
guideline implementation, with similarities and differences
identified across studies. The most commonly occurring
barriers were ‘Environmental context and resources’
(n = 14), ‘Social influences’ (n = 13), ‘Beliefs about con-
sequences’ (n = 11), ‘Knowledge’ (n = 11) and ‘Social
professional role and identity’ (n = 9). The most com-
monly occurring facilitators were ‘Beliefs about conse-
quences’ (n = 11), ‘Social professional role and identity’
(n = 8), ‘Knowledge’ (n = 8) and ‘Social influences’
(n = 7). Many TDF domains were identified as both bar-
riers and facilitators within the same studies. ‘Beliefs
about consequences’ (n = 9), ‘Knowledge’ (n = 7) and
‘Social influences’ (n = 7) were most frequently identified
© 2020 The Authors. International Journal of Pharmacy Practice
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as both barriers and facilitators. The frequency of each
TDF domain occurrence is illustrated in Figure 2.
Due to the heterogeneity of the studies, a narrative
analysis was undertaken. Studies were grouped and
reported by patient type or prescribing topic. The TDF
domains identified by each study as barriers and facilita-
tors to guideline adoption are presented in Table 2.
Paediatrics
Four studies investigated prescribing in children and
infants.[23–26] ‘Social influences’ was reported as a barrier
in all four studies.[23–26] Parental pressures imposed diffi-
culties in guideline adherence as most prescribers were
afraid of parents losing trust and seeking a prescription
elsewhere. Peer influences also acted as a barrier due to
differences in colleagues’ opinions[26] and senior influ-
ences.[24] Lack of knowledge (‘Knowledge’) was also sig-
nificant in three studies[23,25,26] as prescribers lacked
awareness of guidelines and acknowledged the specificity
and complexity of those already in use. ‘Environmental
context and resources’ was identified as a barrier in terms
of time constraints which limited prescribers’ ability to
educate parents and the rationale for following
Figure 1 PRISMA flow diagram.
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guidelines.[23,26] ‘Beliefs about consequences’ was recog-
nised as the most important facilitator identified in three
studies.[23–25] In one study, prescribers were aware that
guidelines improved rationale for prescribing and stan-
dardised care.[24]
Pregnancy and preconception
Three studies examined guideline use in pregnancy and pre-
conception.[27–29] Time constraints and limited resources were
particularly evident in two studies (‘Environmental context
and resources’).[27,29] The former also placed a burden on
clinics if more time was needed to achieve guideline imple-
mentation. Lack of awareness of guidelines (‘Knowledge’) was
also mentioned, as well as conflicting or lack of evidence of
the medication prescribed (‘Beliefs about consequences’).[27,29]
Contrastingly, two studies reported that prescribers believed
guidelines ensured the best outcomes for patients (‘Beliefs
about consequences’).[27,29] ‘Social influences’ was also an
important factor in the studies with the influence of colleagues
acting as both barriers and facilitators depending upon cir-
cumstances.[27,29]
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Number of studies reported as barrier or facilitator
Number of studies reported as barrier
Number of studies reported as facilitator
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Elderly
Three studies examined prescribing for elderly patients in
primary care, two of which explored de-prescribing and
inappropriate prescribing.[30–32] The ‘Beliefs about conse-
quences’ domain was reported in all studies as a bar-
rier.[30–32] Some practitioners believed, for example, that
prescribing antipsychotics to elderly patients would have
negative consequences and, therefore, did not follow
guidelines.[32] Other prescribers chose not to follow
guidelines because of their uncertainty regarding whether
the patient would live long enough to benefit from treat-
ment but also because they were concerned about side
effects and negative impacts on quality of life.[31] All
three studies identified a need for improved communica-
tion, resources and time management for pursuing bet-
ter practice and care (‘Environmental context and
resources’).[30–32]
Co-morbidity
Two studies explored the use of guidelines in patients
with co-morbidities.[21,22] Participants identified that
guidelines were difficult to understand and utilise in prac-
tice (especially by generalist prescribers) (‘Environmental
context and resources’ and ‘Knowledge’).[21,22] Prescribers
reported feeling a lack of competence because they were
prescribing outside their professional role (‘Social profes-
sional role and identity’ and ‘Beliefs about capabili-
ties’).[21,22] This may have been due to inadequate
training and experience within the area. Both studies
acknowledged that patient engagement and preferences
were substantial barriers to guideline compliance as
patients wanted specific medicines prescribed (‘Social
influences’).[21,22] Both studies identified awareness of
guidelines (‘Knowledge’) as a facilitator for guideline
compliance.[21,22] An additional facilitator was the ability
of healthcare professionals to work collaboratively and
access help and support when managing patients with co-
morbidities (‘Social professional role and identity’ and
‘Social influences’).[21,22]
Emergency care
Two studies explored compliance with prescribing guideli-
nes in emergency settings in secondary and tertiary
care.[18,19] Peer influences (‘Social influences’) were appar-
ent in both as barriers and facilitators.[18,19] It was also
noted that guidelines were not relevant to certain patients
(‘Social professional role and identity’ and ‘Beliefs about
consequences’) as recommendations were not sufficiently
inclusive.[18,19] Both studies also identified time limita-
tions as a frequent barrier to guideline complianceTa
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(‘Environmental context and resources’).[18,19] Lack of
training was a barrier; that is, staff had not received train-
ing about the protocol/guidelines (‘Knowledge’ and ‘Beha-
vioural regulation’).[18,19] This made guidelines difficult to
use in a highly time-pressured environment. In both stud-
ies, it was established that guidelines aided prescribers in
being sure of what their role was, and what was expected
of them (‘Social professional role and identity’).[18,19] The
use of guidelines to improve recovery times and outcomes
was identified as facilitators (‘Beliefs about conse-
quences’).[19]
An additional study explored prescribing in dental
emergencies within primary care.[20] A lack of under-
standing of emergency care guidelines (‘Behavioural regu-
lation’) was consistent with other emergency care
studies.[18,19] The study also emphasised the need for
additional training.[20]
Antibiotics
Three studies (reported above) investigated antibiotic pre-
scribing.[20,23,30] One of the most dominant barriers
observed in all studies involved time restrictions
(‘Environmental context and resources’).[20,23,30] This led
to clinicians prescribing antibiotics instead of complying
with guideline recommendations. The ‘Social influences’
domain was also evident in all studies.[20,23,30] Patient and
family fears influenced clinicians’ decision to prescribe
antibiotics contrary to guideline recommendations. Two
studies[20,30] mentioned fear of infection being missed or
exacerbation as a consequence of not providing antibiotic
relief (‘Emotion’ and ‘Beliefs about consequences’). A fur-
ther finding in relation to the latter domain was that
guideline compliance was facilitated if clinicians believed
that antibiotics were not indicated and would not achieve
the desired outcomes.[20,23]
Quality of included studies
No formal assessment was undertaken of the quality of
the included studies; however, from the narrative analysis
it was clear that there was substantial variation in study
quality. For example, the frequency of each behavioural
domain was not always specified. An expressed belief may
have been held by one participant or the majority. The
use of interviewer blinding varied with one study report-
ing interviewee blinding to the type of prescriber,[20]
whereas no blinding was used with the single interviewer
in the study by Gray et al.[24] The sample size varied
across studies, often with small sample sizes being
reported. One study indicated that, despite the sample
size, data saturation was presumed to have been
achieved.[27]
Discussion
To our knowledge, this is the first systematic review of
studies which have used the TDF to explore the key
determinants of the adoption of prescribing guidelines.
Whilst the 15 included studies explored a wide range of
patient populations and health settings, similar domains
were often identified as influencing guideline-compliant
behaviour.
Strengths and limitations
The use of duplicate independent screening and data
extraction reduced the risk of selection bias. Whilst there
was no formal assessment of study quality, it was evident
that quality varied across the included studies. No formal
critical appraisal was undertaken; however, specific limita-
tions of studies were highlighted, such as unspecified
behavioural domain occurrence, variations in interviewer
blinding and differences in sample sizes. No studies were
excluded for quality reasons.
General findings
One of the dominant barriers was lack of time, identified
in more than half of the studies.[19,20,22,23,26–29] Time
restrictions impeded full engagement with patients and
the use of consultation time appropriately hindering
guideline use. This barrier has been acknowledged fre-
quently in previous systematic reviews of barriers to
guideline implementation[12,14] but one which could
potentially be overcome by standing orders and financial
incentives.[33]
Lack of awareness and understanding of guidelines was
also a barrier identified in many of the included stud-
ies.[18–20,22,26,27,29,30] A systematic review by Francke
et al.[12] suggested that it is not sufficient to merely dis-
seminate a guideline by policy makers and implementers,
but that practitioners should be directed and actively
involved in implementation strategies that increase aware-
ness and familiarity with the guidelines.[12]
Guideline complexity was previously identified as the
most frequent barrier to guideline use.[12] Several studies
in the current review reflect this finding.[18–20,24,27]
This was particularly evident in this review in terms of
studies undertaken in emergency care, all of which
mentioned guideline complexity as a major barrier in a
highly time-pressured environment.[18,19] Similarly, the
included studies that explored prescribing in co-morbid-
ity also identified complexity as a barrier and suggested
that guideline simplification was necessary for generalist
use.[21,22]
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Social influences were frequently identified as barri-
ers.[20–26,30] Family anxiety was especially apparent in
studies of paediatric[23,26] and elderly[30] patients. Health-
care professionals were unable to comply with recommen-
dations due to the fear of family members losing trust or
seeking prescriptions elsewhere.[23] Moreover, patients
refused treatment[22] or arrived in the consultation room
expecting specific medicines to be prescribed.[20]
Lack of evidence was a barrier in multiple stud-
ies.[18,21,27–29,31] Clinicians preferred to use their clinical
expertise in preference to guidelines that lacked sufficient
evidence. Interestingly, all studies concerning pregnancy
and preconception identified this barrier.[27–29] However,
some studies also recognised a lack of clarity regarding
how to use the evidence in specific populations.[18,19,29]
Van Peet et al.[31] acknowledged that guidelines were not
applicable for the older population leading to uncertainty
in prescribing. Previous findings have established that
most clinical guidelines today are disease-specific and fail
to address the intricacies and heterogeneity of managing
older patients.[34] This suggests the need for more indi-
vidualised guidelines that prioritise therapies and goals of
more complex patients.[34]
Our review found that some clinicians disagreed with
guidelines and simply chose not to use them in prac-
tice.[18,21,28] Discrepancies in colleagues’ opinions had an
impact on guideline adoption.[18,19,27,29] Brassard et al.[18]
highlighted the need for improvement in inter-profes-
sional communication to increase awareness of existing
guidelines. The influence of colleagues, however, also
acted as a facilitator in several secondary and tertiary care
studies.[18,19,24,25,27,29] The acceptance of guideline-based
therapy by peers reassured practitioners and, therefore,
promoted guideline use.[18]
Simple and easy-to-use guidelines facilitated prescribing
emphasising the need for guideline simplification.[27,19,29,20]
Some studies also acknowledged that guidelines provided
confidence within prescribers and were viewed as instru-
mental in standardising care.[18,22,24,26] Several studies iden-
tified that guidelines improved patient outcomes which
facilitated their use.[19,27,31] The use of checklists and action
plans ensured that guidelines were utilised in primary care
patient consultations.[22,26,28]
Future research, policy and practice
The barriers to guideline compliant prescribing most fre-
quently identified in this systematic review were time con-
straints, lack of understanding and/or awareness, lack of
clinical evidence, and social influences. Policymakers who
invest in the development of guidelines need to plan and
adopt effective implementation strategies to achieve their
desired objectives. Guidelines that are succinct and easy-to-
use may improve their adoption. Training programmes
and resources to promote dissemination and understanding
of guidelines should be considered. Transparency is needed
regarding the evidence from which guidelines are derived.
Guideline implementation strategies that are successful
in one setting may fail in others because barriers may dif-
fer.[14] For example, this review demonstrated the impor-
tance of social influences in prescribing associated with
paediatric populations. Where social influences are likely
to be key determinants for the uptake of guideline recom-
mendations, interventions might be required to influence
patient and public behaviour in addition to prescribing
behaviours. As such, research that targets identified
healthcare settings and patient populations may provide
further evidence to increase the specificity and credibility
of intervention strategies.
Conclusion
Multiple behavioural factors affect the adoption of pre-
scribing guidelines. Interventions that fail to address the
most commonly encountered barriers are less likely to
influence guideline adoption and achieve the desired
improvements in patient outcome. This review investi-
gated barriers and facilitators that affect guideline imple-
mentation from a theoretical perspective. It aided the
understanding of influencing factors that may be targeted
to increase guideline compliance.
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